Czech Republic: Europe's New Biotech Corridor at BIO 2005
Related News: Stem Cell ResearchSAN MATEO, CA -- (MARKET WIRE) -- 05/19/2005 -- CzechInvest, the Investment and Business Development Agency of the Czech Republic, today announced the Czech Republic will showcase leading Czech-based biotechnology companies at the upcoming Biotechnology Industry Organization (BIO) annual convention, BIO 2005, June 19-22 at the Pennsylvania Convention Center in Philadelphia.
"The Czech Republic is becoming the biotechnology corridor of Central and Eastern Europe," says Radomil Novák, Chief Executive Officer of CzechInvest. "This emergent technology sector is garnering international acclaim for its breakthroughs in stem cell research, hepatitis and AIDS (HIV) treatments, and for leading-edge biotechnology-nanotechnology processes."
The Czech biotechnology sector is internationally recognized for its world-renowned discoveries and breakthroughs in the sciences, including:
Dr. Antonin Holy, whose work in the development of new treatments for the suppression of AIDS (HIV) and hepatitis at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic resulted in 2001 and 2002 U.S. Food and Drug Administration approval of Viread, a treatment for AIDS, and Hepsera, a B-hepatitis drug. Both were produced by Gilead Sciences and based on a compound discovered in Dr. Holy's Prague laboratory.Czech Republic experts who lead cutting-edge research into the controversial area of human embryonic stem cells. For example, Doctor Ptr Dvorak and his team made international headlines in 2003 when they isolated a new line of human embryonic stem cells, or ESLs. Many laboratories worldwide have tried to derive human ESLs and only three have accomplished this critical step. The leading international scientific journal in the field, "Stem Cells" is slated to publish a paper detailing Dvorak's latest findings, which focus on a potential mechanism for keeping human stem cells in their original "blank" state...
Posted on May 27, 2005 08:52 AM